Notice of Intent (NOI) registration OPEN
- 10am, 1 April 2020 (Wednesday)
Draft Grant Proposal due to RIC for strategic review. Early submission encouraged.
- 10am, 1 April 2020 (Wednesday)
Draft application due to RIC for compliance and eligibility check (including other supporting documents, if applicable
- 10am, 3 Apr 2020 (Friday)
Authority to Submit due to RIC
- 5pm, 13 Apr 2020 (Monday)
Final application submitted to RIC
- 12pm, 14 Apr 2020 (Tuesday)
Final application submitted to NHMRC
The objective of the 2020 Respiratory Medicine Clinical Trials Research on COVID-19 Grant Opportunity is to use clinical trials to accelerate the implementation of treatments for severe acute respiratory distress in patients infected with COVID-19.
Applications to this grant opportunity must propose a clinical trial that accelerates the implementation of treatments for severe acute respiratory distress in patients infected with COVID-19 in order to support the response to the COVID-19 outbreak in Australia. Applicants should note that the research funded by this grant opportunity is not intended to be used for development of vaccines or anti-viral therapies for COVID-19. These issues are the subject of separate MRFF grant opportunities.
Given the rapidly evolving nature of the COVID-19 outbreak, applicants must propose clinical trials that will support the rapid implementation of new treatments for COVID-19, including demonstration of access to relevant clinical trial networks, patient cohorts and other critical resources to allow for rapid progression of the product into clinical practice. Applicants must provide evidence of the feasibility of quickly implementing their proposed intervention, including the target population, potential timeframes, workforce adaption, overall project costs, and how it will be made available to the Australian public (e.g. via existing reimbursement pathways).
The intended outcome of the research funded under this priority is to use clinical trials to accelerate the implementation of safe and effective treatments for severe acute respiratory distress in patients infected with COVID-19. This includes the identification of plausible pathways to clinical practice within 12 months of commencement.
To be competitive for funding, applicants must propose a clinical trial that delivers against the above objective. If applicants propose a clinical trial that is not relevant to the desired outcome they will be considered against the assessment criteria and found to be uncompetitive. Administering Institutions are requested to ensure they only submit applications that address the desired outcomes.
For this grant opportunity, up to $5 million of funding through the Medical Research Future Fund is available in 2019-20.
The project must be completed by 30 June 2021.
- The research funded by this grant opportunity is not intended to be used for development of vaccines or anti-viral therapies for COVID-19. These issues are the subject of separate MRFF grant opportunities
- A person must not be named as a Chief Investigator (CI) on more than one application submitted to this grant opportunity.
- The proposed research should not duplicate research previously or currently being undertaken. The NHMRC may compare the research proposed in grant applications with grants previously or currently funded by the MRFF, NHMRC or other agencies (e.g. Australian Research Council) and published research (see also section 4.7 – Other ineligible expenditure)
How to apply
- Notice of Intent: Please register your Notice of Intent if you are considering applying for the this grant opportunity. RIC-MRFF team will then contact each applicant with further information.
- Update/complete Sapphire Profile: Each CI will need to obtain access to the Sapphire to complete this step. Applicants (including all Chief Investigators and Associate Investigators) are required to submit a registration form available on the Sapphire Landing Page. NHMRC copied RGMS users’ CV/Profile data from RGMS for migration into Sapphire on Wednesday 12 February 2020 after 5.00pm (AEDT). Any changes made to an RGMS profile after this date have not been replicated in Sapphire.
- Review documentation: Review the grant guidelines and category descriptors available below and at Grant Connect.
- Create and Complete the application: Log in to Sapphire, select the relevant grant opportunity to complete the application.
- Submit “Review Ready” application to RIC: Submit application to RIC within the RIC internal submission period for review.
- Complete application: After taking feedback from the RIC team into consideration, complete the application in RGMS. It is suggested advice is sought from colleagues, Faculty Mentors, etc. before finalising the application.
- Submit the UoM Authority to Submit Form:
This form must be submitted to RIC electronically by the final internal closing date. The form should include:
- CIA and Head of Department/Institute Director signatures
Written evidence (e.g. email) from all CIs and AIs is no longer required for applications submitted via Sapphire. Accepting an invitation to participate in an application constitutes a written agreement to be named on an application. CIAs cannot submit an application for RAO certification until all research team members on their application have accepted the invitation.
This is an NHMRC requirement and the application cannot be submitted to NHMRC until received.
On the final internal closing date, the applicant must:
- Certify the application via the ‘Certification’ function in the left panel of your Sapphire application. The applicant will be given the opportunity to download their application and attachments prior to the two-stage confirmation prompt before submission. The application will be locked once certified and status then will be Submitted to RAO.
- Email RIC email@example.com as well as a scanned, signed Authority to Submit form.
- Should you require further information please contact Alvin Wong on 83449352 or via email
Summary and Tips - Please contact the MRFF team to discuss